Clinical Trial Update: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating sequential therapy with Daplusiran/Tomligisiran (DAP/TOM) followed by Bepirovirsen for chronic hepatitis B, with the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Bepirovirsen
• Daplusiran/Tomligisiran (DAP/TOM)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Chronic Hepatitis B Virus Infection, Hepatitis B | Phase 2 | Status: ACTIVE_NOT_RECRUITING